Patents by Inventor Yubo Zhou

Yubo Zhou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10933063
    Abstract: Bruton's tyrosine kinase (Btk) inhibitors have the following Formula (I):
    Type: Grant
    Filed: May 22, 2019
    Date of Patent: March 2, 2021
    Assignees: Suzhou Baijibugong Pharmaceutical Technology Co., Ltd.
    Inventors: Xibin Liao, Jia Li, Zhijian Lu, Yubo Zhou, Anhui Gao
  • Patent number: 10836743
    Abstract: Provided is a fluorinated cyclopropylamine compound represented by formula I, a racemate thereof, an R-isomer thereof, an S-isomer thereof, a pharmaceutical salt thereof, and a mixture thereof. Also provided are pharmaceutical compositions containing the compound, a preparation method for the compound, and uses thereof as a lysine specific demethylase 1 (LSD1) inhibitor, and in the treatment of cancers.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: November 17, 2020
    Assignee: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Hong Liu, Jia Li, Jiang Wang, Mingbo Su, Shuni Wang, Yubo Zhou, Wei Zhu, Wei Xu, Chunpu Li, Hualiang Jiang, Kaixian Chen
  • Patent number: 10822327
    Abstract: A 2-substituted aromatic ring-pyrimidine derivative as shown in a general formula I, and an optical isomer or a pharmaceutically acceptable salt or a solvate thereof are provided. The present invention designs and synthesizes a series of novel small molecular Chk1 inhibitors by using N-substituted pyridin-2-aminopyrimidine obtained through structure-based virtual screening as a lead compound, and carries out Chk1 kinase inhibitory activity test. The experiment confirmed that said compounds possess strong anti-cancer effect, Chk1 kinase inhibitory activity and are promising Chk1 inhibitors. The compounds can be used as new cancer therapeutic drugs, which can be applied to treat solid tumors or hematologic tumors related to proliferative disease of human or animal.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: November 3, 2020
    Assignees: ZHEJIANG UNIVERSITY, SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Tao Liu, Jia Li, Yongzhou Hu, Yubo Zhou, Xiaowu Dong, Anhui Gao, Pinrao Song, Peipei Wang, Lexian Tong, Xiaobei Hu, Mingbo Su
  • Publication number: 20200334699
    Abstract: Systems and methods are described to determine anomalies and identify segments associated with the anomalies. Surveys are collected over a period of time to create historical data. The surveys include questions related to customer experience (“CX”) and questions that can be used to divide the customers into one or more segments. When a survey is received from a customer, the scores of the survey are compared with scores of the historical data (and other currently received scores) to determine if the scores associated with a survey are associated with an anomaly. Once an anomaly is detected, the segments associated with the surveys corresponding to the anomaly are analyzed to determine which segments are associated with the anomaly. The determined segments can be used to correct, solve, or explain the anomaly.
    Type: Application
    Filed: April 16, 2020
    Publication date: October 22, 2020
    Inventors: Yubo Zhou, Baratwajan Shrinevas, Abdel Dridi, Teja Potineni, Hong Wang, Anouar Dziri, Saranya Hemakumar, Andrew Fong
  • Patent number: 10793566
    Abstract: Bruton's tyrosine kinase (Btk) inhibitors have the following Formula (I):
    Type: Grant
    Filed: May 22, 2019
    Date of Patent: October 6, 2020
    Assignees: ZIBO BIOPOLAR CHANGSHENG PHARMACEUTICAL CO. LTD., SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Xibin Liao, Jia Li, Zhijian Lu, Yubo Zhou, Anhui Gao
  • Publication number: 20200299265
    Abstract: The invention relates to a compound of formula (I) in free form or in pharmaceutically acceptable salt form to pharmaceutical compositions comprising said compound and to the use of said compound in the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva.
    Type: Application
    Filed: May 27, 2020
    Publication date: September 24, 2020
    Inventors: Luca ARISTA, Sreehari BABU, Jianwei BIAN, Kai CUI, Michael Patrick DILLON, Rene LATTMANN, Jialiang LI, Lv LIAO, Dimitrios LIZOS, Rita RAMOS, Nikolaus Johannes STIEFL, Thomas ULLRICH, Peggy USSELMANN, Xiaoyang WANG, Liladhar Murlidhar WAYKOLE, Sven WEILER, Yubo ZHANG, Yizong ZHOU, Tingying ZHU
  • Patent number: 10766889
    Abstract: The invention describes an aryl-2,2?-tandem bisthiazole compound and a preparation method and the use thereof. In particular, disclosed in the present invention are an aryl-2,2?-tandem bisthiazole compound with the structure as shown in general formula I and the preparation method thereof and use thereof as a histone deacetylase inhibitor in the preparation of antitumor drugs.
    Type: Grant
    Filed: August 24, 2017
    Date of Patent: September 8, 2020
    Assignee: Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    Inventors: Fajun Nan, Jia Li, Jian Ding, Meiyu Geng, Yangming Zhang, Yi Chen, Yubo Zhou, Chaojun Gong, Mingbo Su, Anhui Gao
  • Publication number: 20200247757
    Abstract: The present invention relates to compounds of Formula I, a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).
    Type: Application
    Filed: April 21, 2020
    Publication date: August 6, 2020
    Inventors: Donatella CHIANELLI, Runyan LI, Valentina MOLTENI, John NELSON, Jason Thomas ROLAND, Paul Vincent RUCKER, David Charles TULLY, Xiaoyang WANG, Liladhar Murlidhar WAYKOLE, Yubo ZHANG, Bo ZHOU
  • Publication number: 20200229180
    Abstract: This application provides a data transmission method and a communications apparatus. The method includes: receiving uplink resource configuration information including information about at least two uplink reference points, and one uplink reference point corresponds to one uplink carrier; and determining, based on the uplink resource configuration information, an uplink carrier on which an uplink transmission resource is located.
    Type: Application
    Filed: March 27, 2020
    Publication date: July 16, 2020
    Inventors: Zhe Liu, Guohua Zhou, Yubo Yang, Yi Long, Zhang Zhang, Jinlin Peng, Zhenfei Tang
  • Patent number: 10710980
    Abstract: The invention relates to a compound of formula (I) in free form or in pharmaceutically acceptable salt form (I) to pharmaceutical compositions comprising said compound and to the use of said compound in the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva.
    Type: Grant
    Filed: July 18, 2017
    Date of Patent: July 14, 2020
    Assignee: Novartis AG
    Inventors: Luca Arista, Sreehari Babu, Jianwei Bian, Kai Cui, Michael Patrick Dillon, Rene Lattmann, Jialiang Li, Lv Liao, Dimitrios Lizos, Rita Ramos, Nikolaus Johannes Stiefl, Thomas Ullrich, Peggy Usselmann, Xiaoyang Wang, Liladhar Murlidhar Waykole, Sven Weiler, Yubo Zhang, Yizong Zhou, Tingying Zhu
  • Publication number: 20200178224
    Abstract: Embodiments provide an information processing method and a terminal device, so that a network device can indicate a reserved resource, and the terminal device can process the reserved resource. In these embodiments, configuration information of a reserved resource sent by a network device can be received by a terminal device. The terminal device can determine, based on the configuration information of the reserved resource, that a resource type of the reserved resource is a first-type reserved resource or a second-type reserved resource. The terminal device can determine a radio frequency processing manner on the reserved resource based on the resource type.
    Type: Application
    Filed: February 4, 2020
    Publication date: June 4, 2020
    Inventors: Yubo YANG, Guohua ZHOU, Yinan ZHAO
  • Patent number: 10662187
    Abstract: Bruton's tyrosine kinase (Btk) inhibitors have the following Formula (I):
    Type: Grant
    Filed: January 17, 2017
    Date of Patent: May 26, 2020
    Assignees: Zibo Biopolar Changsheng Pharmaceutical Co. Ltd., Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    Inventors: Xibin Liao, Jia Li, Zhijian Lu, Yubo Zhou, Anhui Gao
  • Publication number: 20190389161
    Abstract: This disclosure provides a method for manufacturing a silver-plated reflecting film. The method includes following steps: (1) manufacturing a reflecting polyester film layer; (2) coating a silver-plated layer on one surface of the reflecting polyester film layer by a vacuum sliver plating method, wherein the vacuum sliver plating methods comprises a vacuum evaporation plating method or a vacuum sputtering silver plating method; and (3) applying a protection layer film on the silver-plated layer and obtaining the silver-plated reflecting film.
    Type: Application
    Filed: August 27, 2019
    Publication date: December 26, 2019
    Inventors: Yadong Jin, Yubo Zhou
  • Publication number: 20190375727
    Abstract: A 2-substituted aromatic ring-pyrimidine derivative as shown in a general formula I, and an optical isomer or a pharmaceutically acceptable salt or a solvate thereof are provided. The present invention designs and synthesizes a series of novel small molecular Chk1 inhibitors by using N-substituted pyridin-2-aminopyrimidine obtained through structure-based virtual screening as a lead compound, and carries out Chk1 kinase inhibitory activity test. The experiment confirmed that said compounds possess strong anti-cancer effect, Chk1 kinase inhibitory activity and are promising Chk1 inhibitors. The compounds can be used as new cancer therapeutic drugs, which can be applied to treat solid tumors or hematologic tumors related to proliferative disease of human or animal.
    Type: Application
    Filed: November 8, 2017
    Publication date: December 12, 2019
    Inventors: Tao Liu, Jia Li, Yongzhou Hu, Yubo Zhou, Xiaowu Dong, Anhui Gao, Pinrao Song, Peipei Wang, Lexian Tong, Xiaobei Hu, Mingbo Su
  • Publication number: 20190349144
    Abstract: A transmission mode switching method and apparatus are provided. The method includes receiving, by a terminal, transmission mode configuration information sent by a base station, where the transmission mode configuration information includes a configuration parameter of a target transmission mode, and setting, by the terminal, a current uplink transmission mode to the target transmission mode if the terminal detects, through listening, trigger signaling in preset space. When uplink data transmission supports multiple transmission modes, switching between the multiple transmission modes can be implemented.
    Type: Application
    Filed: July 25, 2019
    Publication date: November 14, 2019
    Inventors: Yubo YANG, Guohua ZHOU, Yinan ZHAO, Lei LIU
  • Publication number: 20190275037
    Abstract: Bruton's tyrosine kinase (Btk) inhibitors have the following Formula (I):
    Type: Application
    Filed: May 22, 2019
    Publication date: September 12, 2019
    Inventors: Xibin LIAO, Jia LI, Zhijian LU, Yubo ZHOU, Anhui GAO
  • Publication number: 20190276453
    Abstract: Bruton's tyrosine kinase (Btk) inhibitors have the following Formula (I):
    Type: Application
    Filed: May 22, 2019
    Publication date: September 12, 2019
    Inventors: Xibin LIAO, Jia LI, Zhijian LU, Yubo ZHOU, Anhui GAO
  • Patent number: 10358446
    Abstract: Bruton's tyrosine kinase (Btk) inhibitors have the following Formula (I):
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: July 23, 2019
    Assignees: ZIBO BIOPOLAR CHANGSHENG PHARMACEUTICAL CO., LTD., SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Xibin Liao, Jia Li, Zhijian Lu, Yubo Zhou, Anhui Gao
  • Patent number: D870891
    Type: Grant
    Filed: October 2, 2018
    Date of Patent: December 24, 2019
    Assignee: Ningbo Xinwell Medical Technology Co., Ltd
    Inventors: Yubo Zhou, Jiewei Yu
  • Patent number: D873415
    Type: Grant
    Filed: October 1, 2018
    Date of Patent: January 21, 2020
    Assignee: Ningbo Xinwell Medical Technology Co., Ltd
    Inventors: Yubo Zhou, Jiewei Yu